查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1840834

兽用抗感染药感染疾病市场依产品类型、给药途径、动物类型、通路和应用划分－全球预测，2025-2032年

Veterinary Anti-infectives Market by Product Type, Route Of Administration, Animal Type, Distribution Channel, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，兽用感染疾病市场规模将成长 109 亿美元，复合年增长率为 12.38%。

关键市场统计数据
基准年 2024 42.8亿美元
预计年份：2025年 48.1亿美元
预测年份 2032 109亿美元
复合年增长率 (%) 12.38%

本文简要概述了不断发展的兽用抗感染疾病领域，阐述了影响该领域策略的临床需求、管理压力和商业性因素。

兽用感染疾病物产业正处于曲折点，科学进步、动物健康优先事项的转变以及不断变化的监管和贸易环境正在改变产品的研发、分销和使用方式。本导论简要说明了影响伴侣动物、牲畜、家禽和水产养殖中抗生素、抗真菌药物和抗寄生虫药物治疗的关键因素。它重点关注临床需求、管理要求和商业性现实之间的相互作用，为深入分析市场动态和战略意义奠定了基础。

随着动物健康系统不断应对抗菌素抗药性、生物安全标准提高以及供应链变化等压力，相关人员必须权衡短期营运挑战与长期投资决策。将临床疗效、安全性和合理使用相结合的综合方法日益成为产品定位的核心。此外，从数位诊断到精准给药系统等技术赋能手段正在改变新疗法和现有治疗方法的价值提案。透过重点阐述这些因素，读者将理解为何跨职能协作、数据主导的决策以及敏捷的商业化策略对于在快速变化的环境中维持成长并确保治疗相关性至关重要。

确定影响兽用感染疾病物转型的关键驱动因素，包括诊断、管理、供应弹性以及数位分销动态

在科学创新、监管趋严和相关人员期望转变的推动下，兽用感染疾病物领域正经历变革性的转变。诊断技术的进步加速了从经验性治疗到标靶治疗的转变，使兽医能够更精准地选择药物，同时减少不必要的用药。同时，抗菌药物管理也受到越来越多的关注，监管机构和采购方要求提供更清晰的证据，以证明药物的合理使用和风险缓解策略，这正在影响处方决策和行为。

同时，供应链正经历一段重新调整期。优先考虑地域多元化、品质保证和供应商透明度的筹资策略正逐渐成为标准做法。数位化平台和远端医疗也在扩大兽医咨询和治疗管理的覆盖范围，创造了新的通路，同时也引发了关于有效监管的疑问。对新型治疗方法和製剂技术的公共和私人投资持续成长，但对健全的上市后监测和生命週期管理的需求也日益增加。总而言之，这些变化迫使製造商重新思考其产品开发重点、监管互动和商业模式，以在既重视疗效又重视负责任管理的环境中保持竞争力并遵守相关法规。

分析关税变化和贸易政策转变如何影响整个价值链的供应链决策、定价策略和风险缓解措施。

关税和贸易政策的实施为兽用感染疾病的商业环境带来了新的复杂性。关税调整可能会影响生产布局、采购决策和定价策略，促使生产商和经销商重新评估其全球供应链。为此，许多公司正在考虑近岸外包、双重采购和库存优化等措施，以减轻关税相关成本波动的影响，并维持关键治疗药物的持续供应。

这些政策主导的转变将与现有的监管和市场压力相互作用，影响製造外包、库存分配和市场通路结构的决策。拥有垂直整合供应链和多元化生产基地的公司通常更有能力吸收不断上涨的关税成本，而无需将全部负担转嫁给最终客户。相反，依赖单一来源进口或高销售量、低利润产品线的公司可能面临利润率压缩，需要进行策略性重新定价、重新谈判供应商条款或调整通路奖励。在这些情况下，情境规划和关税影响建模对于希望在保障基本抗感染疾病治疗药物供应的同时，维持商业性可行性并协调相关人员预期的领导者而言，至关重要。

基于产品类型、给药途径、动物类别、分销管道和应用场景等深度主导洞察，产品策略得以建构。

细分市场层面的洞察揭示了不同产品类型、给药途径、动物类别、分销管道和应用领域之间的差异化动态，这些因素共同影响研发重点和市场推广策略。就产品类型而言，抗生素仍然是核心，但它们的内部发展轨迹各不相同。Aminoglycosides、β-内酰胺类、Fluoroquinolones、大环内酯类、磺胺类药物和四环霉素均面临管理和监管方面的考量，这些考虑会影响标籤、停药期和使用指南。抗真菌药物物（分为Azole和Polyenes）需要精细的製剂策略，以平衡局部和全身给药的疗效和安全性。抗寄生虫药物（包括杀螨剂、驱虫剂和杀虫剂）的研发越来越多地考虑到抗药性和环境影响，指南研究方向转向新的化学实体及其在综合虫害管理中的应用。

给药途径进一步影响药物的采纳和产品开发选择。注射剂型，例如肌肉注射、静脉注射和皮下注射，通常优先用于急性护理和住院动物；而口服剂型，例如颗粒剂、粉剂、混悬剂和片剂，则更适合牛管理和伴侣动物护理中的便捷给药。外用剂型，例如乳膏、浸剂、软膏和喷雾剂，在皮肤病和体外寄生虫的治疗中发挥至关重要的作用，因为局部作用和快速起效至关重要。水产养殖（鱼虾）需要水稳定性好且环境友善的製剂；伴侣动物（猫狗）优先考虑安全性和易于饲主使用的给药方式；牲畜（牛、羊、山羊和猪）强调停药期和群体给药的实用性；家禽（鸡和火鸡）则需要将解决方案整合到畜群健康管理通讯协定中。线上药局、实体药局、兽医诊所和动物医院各自面临不同的监管环境、利润结构和客户参与模式。此外，预防用途与治疗用途也会影响产品定位、证据要求和相关人员沟通：预防用途需要在监管框架下接受更严格的审查，而治疗用途则需要可靠的临床疗效数据。

对全球主要地区的监管预期、分销差异和市场准入考虑进行全面的区域分析

区域动态在塑造美洲、欧洲、中东和非洲以及亚太地区的监管预期、供应链设计和商业策略方面发挥关键作用。美洲是一个成熟的动物用药品市场，拥有高标准的监管合规性和完善的分销网络。这促使製造商更加重视证据生成、标籤差异化和基于价值的合同，以适应采购和动物诊疗模式。相较之下，欧洲、中东和非洲地区则呈现异质性。欧洲部分地区需要严格的监管和药物安全检测，而该地区其他市场的监管能力则各不相同，这推动了对适应性打入市场策略的需求日益增长。

亚太地区市场多元化，既有成熟市场，也有快速成长市场。特别是畜牧业集约化和水产养殖业的扩张，大大推动了对高效抗感染疾病解决方案的需求。然而，这种成长也带来了对品质保证和监测的迫切需求，以降低抗药性风险。在任何地区，贸易政策、进口法规以及当地强制性的生产和註册要求的变化都可能对时间表和市场准入选择产生重大影响。因此，区域策略必须在遵循全球标准化的同时，兼顾区域特定法规、区域特定证据包，并与兽医、生产商和经销商进行符合当地文化的沟通。

分析决定抗感染疾病产品组合领导地位和差异化的竞争定位、创新路径和伙伴关係模式

兽用感染疾病市场的竞争格局由成熟的製药公司、专业的动物用药品公司和新兴的生物技术公司组成，它们在研发、生产和商业化方面都采取了独特的策略。老字型大小企业利用其广泛的产品组合、丰富的监管经验和全球分销网络来维持市场地位，而规模较小的公司则往往凭藉针对特定适应症、特殊配方和更快的研发週期来竞争。生物技术参与企业和委外研发机构正透过新型活性成分、标靶给药系统和替代配方等创新手段，为传统化学製剂带来颠覆性挑战。

伙伴关係和策略联盟日益普遍，有助于企业扩大规模、取得专有技术并加速註册流程。投资强大的药物安全检测、抗药性监测和证据生成的公司，更有能力满足不断变化的监管要求，并以可靠的数据支持其药物管理理念。同时，在生产品质、供应链风险管理和数位化互动（例如远端医疗产品支援和数据驱动的给药工具）方面的内部能力，也是市场领导脱颖而出的关键。总而言之，竞争格局有利于那些将科学严谨性与营运韧性相结合，并提供针对特定客户群量身定制的、提案的价值主张的企业。

为产业领导者提供切实可行的优先建议，以增强供应链韧性、证据产生、管理协调和商业性差异化。

产业领导者应采取一系列切实可行的措施，在短期营运韧性和长期策略优势之间取得平衡。首先，透过多元化采购、双通路筹资策略以及严格的供应商品质审核来增强供应链韧性，从而降低关税和贸易中断的影响。其次，将诊断应用案例融入产品开发和商业性定位，以支持标靶治疗、减少不当使用，并强化能够引起监管机构和采购方共鸣的药物管理主张。第三，投资于能够证明长期安全性和价值的证据生成，不仅包括註册试验，还应包括真实世界疗效试验、抗药性监测和药物安全检测。

此外，企业领导者应探索配方和给药方式的创新，以提高用药依从性并减少环境暴露，尤其是在水产养殖和集约化畜牧养殖环境中。从远端医疗处方支援到行动剂量计算器等数位化工具，可以提高用药依从性，并为教育和上市后资料收集提供管道。最后，企业应采用适应性定价和合约策略，既要考虑当地的支付能力限制，也要保留利润空间用于研发再投资。将严谨的营运、临床证据和以客户为中心的商业模式结合，可以帮助企业成功应对监管预期并保持竞争优势。

我们对多来源调查方法进行了透明的解释，该方法结合了专家意见、监管审查和情境分析，从而确保得出可靠且检验的结论。

本分析的调查方法结合了专家定性访谈、二手文献综述以及对监管指南和公开临床证据的结构化综合分析。主要资讯来源包括与兽医、监管专家、生产和供应链高管以及分销合作伙伴的咨询，以了解不同物种和渠道的实践和决策标准。二级资讯来源包括关于抗菌素抗药性的同行评审文献、监管指南文件和行业出版物，以确认其与公认的临床和政策框架的一致性。

我们的分析包括对定性输入资料进行主题编码，以考虑市场细分和评估竞争情况；同时，监管和临床文件使我们能够解读药品管理和安全方面的限制。情境分析探讨了贸易和关税变化对供应链和定价的影响，尤其关注能够维持药品可及性和品质的途径。在整个过程中，我们透过多种资讯来源检验了我们的发现，力求清晰地揭示不确定性，并确保我们的建议是基于可靠的证据和充分的判断。

最后总结强调了製定与管理、供应链韧性、证据产生和商业性模式一致的整合策略的必要性。

总之，兽用感染疾病物市场正受到科学、监管和商业性力量共同作用的重塑，需要产业相关人员采取综合应对措施。抗菌药物管理指令和诊断技术的进步正推动产品研发朝着精准用药和实证医学的方向发展，而政策变化和关税则促使企业建立更具韧性的供应链。产品类型、给药途径、动物种类、分销渠道和使用场景的碎片化表明，一刀切的策略已不再适用，而是需要根据物种特异性需求、当地监管差异和渠道动态制定量身定制的方案。

具有前瞻性的企业将优先投资于支持负责任使用、展现临床和经济价值以及提升营运灵活性的专案。透过将研发重点与管理期望相契合、增强供应链韧性并利用数位化和诊断技术，企业既能满足当前的市场需求，又能建立永续的竞争优势。未来面临的挑战在于，科学、监管和商业部门如何通力合作，将研究成果转化为可执行的方案，在确保有效治疗方法可及性的同时，保护动物和公众健康。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 抗菌素抗药性的日益增强正在推动对新型兽用抗生素和替代疗法的需求。
  • 精准畜牧业的发展推动了标靶抗感染剂传递技术的发展。
  • 更严格的抗生素使用监管推动了噬菌体疗法的普及。
  • 伴侣动物医疗保健成本飙升推动物种特异性感染疾病的创新
  • 兽用疫苗和免疫调节剂的广泛使用减少了对抗生素的依赖。
  • 扩大海外兽用生技药品生产可以提高供应链的韧性。
  • 在诊所中整合抗菌药物管理计划和即时诊断工具
  • 开发长效注射型抗感染製剂以提高治疗顺从性
  • 投资者对利用微生物组调节疗法预防牲畜疾病的兴趣日益浓厚
  • 引入数位监测平台，追踪农场抗生素使用和抗药性趋势

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依产品类型分類的动物感染疾病物市场

  • 抗生素
    • Aminoglycosides
    • β-内酰胺类
    • Fluoroquinolones
    • 大环内酯类
    • 磺胺类药物
    • 四环霉素
  • 抗真菌药物
    • Azole
    • Polyenes
  • 抗寄生虫药物
    • 杀螨剂
    • 驱虫药
    • 杀虫剂

9. 依给药途径分類的动物感染疾病物市场

  • 注射
    • 肌肉内注射
    • 静脉
    • 皮下
  • 口服
    • 颗粒
    • 粉末
    • 暂停
    • 药片
  • 外用药物
    • 奶油
    • 沾
    • 软膏
    • 喷

第十章 依动物类型分類的动物感染疾病物市场

  • 水产养殖
    • 鱼
    • 虾
  • 伴侣动物
    • 猫
    • 狗
  • 家畜
    • 牛
    • 山羊
    • 羊
    • 猪
  • 家禽
    • 鸡
    • 火鸡

第十一章：按分销管道分類的动物感染疾病物市场

  • 网路药房
  • 零售药房
  • 兽医诊所
  • 兽医诊所

第十二章：按应用分類的动物感染疾病物市场

  • 预防
  • 治疗

第十三章：各地区动物感染疾病物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 按类别分類的动物感染疾病物市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国动物感染疾病物市场概况

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Zoetis Inc.
    • Elanco Animal Health Incorporated
    • Merck & Co., Inc.
    • CH Boehringer Sohn AG & Co. KG
    • Intas Pharmaceuticals Ltd.
    • Ceva Sante Animale SA
    • Vetoquinol SA
    • Eco Animal Health Group PLC
    • Virbac SA
    • Sequent Scientific Ltd.
Product Code: MRR-2214614768CF

The Veterinary Anti-infectives Market is projected to grow by USD 10.90 billion at a CAGR of 12.38% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.28 billion
Estimated Year [2025] USD 4.81 billion
Forecast Year [2032] USD 10.90 billion
CAGR (%) 12.38%

Concise orientation to the evolving veterinary anti-infectives sector setting context on clinical needs, stewardship pressures, and commercial imperatives shaping strategy

The veterinary anti-infectives sector is at an inflection point where scientific advances, shifting animal health priorities, and evolving regulatory and trade environments are reshaping how products are developed, distributed, and used. This introduction provides a concise orientation to the core drivers affecting antibiotic, antifungal, and antiparasitic therapies across companion animals, livestock, poultry, and aquaculture. It highlights the interplay between clinical need, stewardship imperatives, and commercial realities, setting the stage for deeper analysis of market dynamics and strategic implications.

As animal health systems adapt to pressures such as antimicrobial resistance concerns, heightened biosecurity standards, and changes in supply chains, stakeholders must reconcile short-term operational challenges with long-term investment decisions. Integrated approaches that combine clinical efficacy, safety, and responsible use are increasingly central to product positioning. Moreover, technological enablers-ranging from digital diagnostics to precision delivery systems-are altering the value proposition for new and existing therapies. Framing these forces up front ensures readers appreciate why cross-functional alignment, data-driven decision-making, and agile commercialization strategies are essential for sustaining growth and ensuring therapeutic relevance in a rapidly changing landscape.

Identification of the major transformative forces reshaping veterinary anti-infectives including diagnostics, stewardship, supply resilience, and digital distribution dynamics

The landscape for veterinary anti-infectives is experiencing transformative shifts driven by scientific innovation, regulatory tightening, and changes in stakeholder expectations. Advances in diagnostic capabilities are accelerating the move from empirical treatment toward targeted therapy, enabling veterinarians to select agents with greater precision while reducing unnecessary use. In parallel, there is intensified scrutiny on antimicrobial stewardship, with regulators and purchasers demanding clearer evidence of appropriate use and risk mitigation strategies, which in turn influences formulary decisions and prescribing behavior.

Concurrently, the supply chain is undergoing recalibration. Sourcing strategies that prioritize geographic diversity, quality assurance, and supplier transparency are becoming standard practices. Digital platforms and telemedicine are also expanding access to veterinary consultation and therapy management, creating new channels for distribution while raising questions about appropriate oversight. Private and public investment in novel modalities and formulation technologies continues to grow, but so does the need for robust post-market surveillance and lifecycle management. Collectively, these shifts are prompting manufacturers to rethink product development priorities, regulatory engagement, and commercial models to remain relevant and compliant in an environment that prizes both efficacy and responsible stewardship.

Analysis of how tariff changes and trade policy shifts are influencing supply chain decisions, pricing strategies, and risk mitigation approaches across the value chain

The introduction of tariffs and trade policy changes has added a new layer of complexity to the operational environment for veterinary anti-infectives. Tariff adjustments can influence manufacturing footprints, sourcing decisions, and pricing strategies, prompting manufacturers and distributors to reassess their global supply chains. In response, many organizations are examining nearshoring, dual-sourcing, and inventory optimization measures to mitigate exposure to tariff-related cost volatility and to preserve supply continuity for critical therapies.

These policy-driven shifts interact with existing regulatory and market pressures, affecting decisions related to contract manufacturing, inventory allocation, and route-to-market structuring. Companies with vertically integrated supply chains or diversified production locations are generally better positioned to absorb incremental tariff costs without passing the full burden onto end customers. Conversely, firms reliant on single-source imports or high-volume, low-margin product lines may face margin compression that requires strategic repricing, renegotiation of supplier terms, or adjusted channel incentives. In this context, scenario planning and tariff-impact modelling become essential tools for leaders seeking to protect access to essential anti-infective treatments while sustaining commercial viability and aligning stakeholder expectations.

Deep segmentation-driven insights across product types, administration routes, animal classes, distribution channels, and application contexts shaping product strategies

Segment-level insights reveal differentiated dynamics across product types, routes of administration, animal classes, distribution channels, and applications that together shape development priorities and go-to-market strategies. Within product type, antibiotics remain central but their internal trajectories diverge: aminoglycosides, beta-lactams, fluoroquinolones, macrolides, sulfonamides, and tetracyclines each face distinct stewardship and regulatory considerations that influence label claims, withdrawal periods, and usage guidelines. Antifungals, segmented into azoles and polyenes, demand nuanced formulation strategies to balance efficacy with safety in both topical and systemic applications. Antiparasitics-spanning acaricides, anthelmintics, and insecticides-are increasingly developed with resistance management and environmental impact in mind, guiding research toward novel chemistries and integrated pest management compatibility.

Route of administration further affects adoption and product development choices. Injectable options, whether intramuscular, intravenous, or subcutaneous, are often prioritized for acute care and hospitalized animals, while oral formulations-pellets, powders, suspensions, and tablets-are tailored for ease of dosing in herd management and companion care. Topical formats such as creams, dips, ointments, and sprays play a pivotal role in dermatological and ectoparasite management where localized exposure and rapid action are critical. Animal type segmentation differentiates clinical pathways and commercial approaches; aquaculture (fish and shrimp) requires water-stable and environmentally considerate chemistries, companion animals (cats and dogs) prioritize safety and owner-friendly dosing, livestock (cattle, goats, sheep, swine) emphasize withdrawal times and mass-administration practicality, and poultry (chicken and turkey) demand solutions that integrate into flock health protocols. Distribution channels shape access and commercial interaction: online pharmacies, retail pharmacies, veterinary clinics, and veterinary hospitals each present different regulatory touchpoints, margin structures, and customer engagement models. Lastly, the application lens-prophylactic versus therapeutic-drives product positioning, evidence requirements, and stakeholder communications, with prophylactic uses prompting additional scrutiny under stewardship frameworks and therapeutic indications necessitating robust clinical efficacy data.

Comprehensive regional analysis of regulatory expectations, distribution nuances, and market access considerations across major global territories

Regional dynamics play a pivotal role in shaping regulatory expectations, supply chain design, and commercial tactics across the Americas, Europe, Middle East & Africa, and Asia-Pacific. The Americas present a mature veterinary market with high standards for regulatory compliance and established distribution networks; manufacturers therefore emphasize evidence generation, label differentiation, and value-based contracting to align with procurement and veterinary practice patterns. In contrast, the Europe, Middle East & Africa region is heterogeneous: parts of Europe demand rigorous stewardship and pharmacovigilance, while other markets in the broader region present variable regulatory capacity and growing demand that calls for adaptable market-entry strategies.

Asia-Pacific features diverse market maturities and rapid growth pockets, especially where livestock intensification and aquaculture expansion amplify demand for effective anti-infective solutions; however, this growth is accompanied by a pressing need for quality assurance and monitoring to mitigate resistance risks. Across all regions, trade policy variations, import controls, and locally mandated manufacturing or registration requirements can materially affect timelines and go-to-market choices. Consequently, regional strategies must balance global standardization with localized regulatory navigation, tailored evidence packages, and culturally informed engagement models with veterinarians, producers, and distributors.

Examination of competitive positioning, innovation pathways, and partnership models that determine leadership and differentiation in anti-infective portfolios

Competitive dynamics in veterinary anti-infectives are shaped by a mix of established pharmaceutical companies, specialized animal health players, and emerging biotech innovators, each pursuing distinct strategies across research, manufacturing, and commercialization. Established firms leverage broad portfolios, regulatory experience, and global distribution networks to maintain market presence, while smaller and mid-sized companies often compete on niche indications, specialized formulations, or faster development cycles. Biotech entrants and contract research organizations contribute innovation in novel active ingredients, targeted delivery systems, and alternative modalities that may disrupt traditional chemistries.

Partnerships and strategic alliances are increasingly common, enabling scale-up, access to proprietary technologies, or acceleration of registration pathways. Companies that invest in robust pharmacovigilance, resistance monitoring, and evidence generation are better equipped to meet evolving regulatory expectations and to support stewardship narratives with credible data. At the same time, internal capabilities in manufacturing quality, supply-chain risk management, and digital engagement-such as telehealth-enabled product support or data-driven dosing tools-differentiate market leaders. Overall, the competitive landscape rewards organizations that combine scientific rigor with operational resilience and compelling value propositions tailored to customer segments.

Practical and prioritized recommendations for industry leaders to strengthen supply resilience, evidence generation, stewardship alignment, and commercial differentiation

Industry leaders should pursue a set of actionable steps that balance near-term operational resilience with long-term strategic advantage. First, fortify supply-chain resilience through diversified sourcing, dual-sourcing strategies, and rigorous supplier quality audits to mitigate tariff and trade disruptions. Second, integrate diagnostic-enabled use cases into product development and commercial positioning to support targeted therapy, reduce inappropriate usage, and strengthen stewardship claims that resonate with regulators and purchasers. Third, invest in evidence generation that goes beyond registration trials to include real-world effectiveness studies, resistance surveillance, and pharmacovigilance that collectively substantiate long-term safety and value.

Moreover, leaders should explore formulation and delivery innovations that improve dosing compliance and reduce environmental exposure, particularly for aquaculture and intensive livestock settings. Digital tools-ranging from telemedicine-enabled prescribing support to mobile dosing calculators-can enhance adherence and provide channels for education and post-market data collection. Finally, adopt adaptive pricing and contracting approaches that recognize regional affordability constraints while preserving margins for reinvestment in R&D. By combining operational rigor, clinical evidence, and customer-centric commercial models, companies can better navigate regulatory expectations and sustain competitive differentiation.

Transparent explanation of the multi-source research methodology combining expert input, regulatory review, and scenario analysis to ensure robust, validated conclusions

The research methodology underpinning this analysis combines qualitative expert interviews, secondary literature review, and structured synthesis of regulatory guidance and public-domain clinical evidence. Primary inputs included consultations with veterinarians, regulatory specialists, manufacturing and supply-chain executives, and distribution partners to capture operational realities and decision criteria across species and channels. Secondary sources encompassed peer-reviewed literature on antimicrobial resistance, regulatory agency guidance documents, and industry publications to ensure alignment with accepted clinical and policy frameworks.

Analysis followed a triangulated approach: thematic coding of qualitative inputs informed segmentation insights and competitive assessments, while regulatory and clinical documents anchored interpretations of stewardship and safety constraints. Scenario analysis was employed to explore the operational implications of trade and tariff changes on supply chains and pricing dynamics, with particular attention to pathways that preserve access and quality. Throughout the process, efforts were made to validate findings against multiple sources and to surface uncertainties explicitly, ensuring that recommendations are grounded in robust evidence and informed judgment.

Final synthesis emphasizing the need for integrated strategies across stewardship, supply resilience, evidence generation, and tailored commercial approaches

In conclusion, the veterinary anti-infectives landscape is being reshaped by a convergence of scientific, regulatory, and commercial forces that require integrated responses from industry stakeholders. Antimicrobial stewardship imperatives and diagnostic advances are redirecting product development toward precision use and robust evidence generation, while policy shifts and tariffs are prompting more resilient supply-chain designs. Segmentation across product types, routes of administration, animal types, distribution channels, and application contexts underscores that one-size-fits-all strategies are no longer sufficient; rather, tailored approaches that address species-specific needs, regional regulatory nuance, and channel-specific dynamics are essential.

Forward-looking organizations will prioritize investments that support responsible use, demonstrate clinical and economic value, and enhance operational flexibility. By aligning R&D priorities with stewardship expectations, strengthening supply-chain resilience, and leveraging digital and diagnostic enablers, companies can both meet immediate market demands and build sustainable competitive advantage. The path forward demands coordination across scientific, regulatory, and commercial functions to translate insights into actionable programs that secure access to effective therapies while safeguarding animal and public health.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising antimicrobial resistance driving demand for novel veterinary antibiotics and alternative therapies
  • 5.2. Growth in precision livestock farming boosting targeted anti-infective delivery technologies
  • 5.3. Increasing regulatory scrutiny on antibiotic use fueling adoption of bacteriophage therapies
  • 5.4. Surge in companion animal healthcare spending driving innovation in species-specific anti-infectives
  • 5.5. Widespread adoption of veterinary vaccines and immunomodulators reducing antibiotic reliance
  • 5.6. Expansion of offshore veterinary biologics manufacturing enhancing supply chain resilience
  • 5.7. Integration of point-of-care diagnostic tools with antibiotic stewardship programs in clinics
  • 5.8. Development of long-acting injectable anti-infective formulations to improve treatment compliance
  • 5.9. Rising investor interest in microbiome modulation therapies for livestock disease prevention
  • 5.10. Implementation of digital monitoring platforms to track antibiotic usage and resistance trends on farms

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary Anti-infectives Market, by Product Type

  • 8.1. Antibiotics
    • 8.1.1. Aminoglycosides
    • 8.1.2. Beta Lactams
    • 8.1.3. Fluoroquinolones
    • 8.1.4. Macrolides
    • 8.1.5. Sulfonamides
    • 8.1.6. Tetracyclines
  • 8.2. Antifungals
    • 8.2.1. Azoles
    • 8.2.2. Polyenes
  • 8.3. Antiparasitics
    • 8.3.1. Acaricides
    • 8.3.2. Anthelmintics
    • 8.3.3. Insecticides

9. Veterinary Anti-infectives Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Intramuscular
    • 9.1.2. Intravenous
    • 9.1.3. Subcutaneous
  • 9.2. Oral
    • 9.2.1. Pellets
    • 9.2.2. Powders
    • 9.2.3. Suspensions
    • 9.2.4. Tablets
  • 9.3. Topical
    • 9.3.1. Creams
    • 9.3.2. Dips
    • 9.3.3. Ointments
    • 9.3.4. Sprays

10. Veterinary Anti-infectives Market, by Animal Type

  • 10.1. Aquaculture
    • 10.1.1. Fish
    • 10.1.2. Shrimp
  • 10.2. Companion Animal
    • 10.2.1. Cats
    • 10.2.2. Dogs
  • 10.3. Livestock
    • 10.3.1. Cattle
    • 10.3.2. Goats
    • 10.3.3. Sheep
    • 10.3.4. Swine
  • 10.4. Poultry
    • 10.4.1. Chicken
    • 10.4.2. Turkey

11. Veterinary Anti-infectives Market, by Distribution Channel

  • 11.1. Online Pharmacies
  • 11.2. Retail Pharmacies
  • 11.3. Veterinary Clinics
  • 11.4. Veterinary Hospitals

12. Veterinary Anti-infectives Market, by Application

  • 12.1. Prophylactic
  • 12.2. Therapeutic

13. Veterinary Anti-infectives Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Veterinary Anti-infectives Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Veterinary Anti-infectives Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Zoetis Inc.
    • 16.3.2. Elanco Animal Health Incorporated
    • 16.3.3. Merck & Co., Inc.
    • 16.3.4. C.H. Boehringer Sohn AG & Co. KG
    • 16.3.5. Intas Pharmaceuticals Ltd.
    • 16.3.6. Ceva Sante Animale SA
    • 16.3.7. Vetoquinol SA
    • 16.3.8. Eco Animal Health Group PLC
    • 16.3.9. Virbac SA
    • 16.3.10. Sequent Scientific Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. VETERINARY ANTI-INFECTIVES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. VETERINARY ANTI-INFECTIVES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VETERINARY ANTI-INFECTIVES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY BETA LACTAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY BETA LACTAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY MACROLIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY MACROLIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SULFONAMIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SULFONAMIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SULFONAMIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SULFONAMIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SULFONAMIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TETRACYCLINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AZOLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AZOLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AZOLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AZOLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AZOLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POLYENES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POLYENES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POLYENES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POLYENES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POLYENES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POLYENES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ACARICIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ACARICIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ACARICIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ACARICIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ACARICIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ACARICIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTHELMINTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTHELMINTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTHELMINTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTHELMINTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTHELMINTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTHELMINTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INSECTICIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INSECTICIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INSECTICIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INSECTICIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INSECTICIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INSECTICIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PELLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PELLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PELLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PELLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PELLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PELLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POWDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POWDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POWDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POWDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POWDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUSPENSIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CREAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CREAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CREAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CREAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CREAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY OINTMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY OINTMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SPRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SPRAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SPRAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SPRAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SPRAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SPRAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AQUACULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AQUACULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY FISH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY FISH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY FISH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY FISH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY FISH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY FISH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SHRIMP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SHRIMP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SHRIMP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SHRIMP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SHRIMP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SHRIMP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COMPANION ANIMAL, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COMPANION ANIMAL, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COMPANION ANIMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COMPANION ANIMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COMPANION ANIMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COMPANION ANIMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COMPANION ANIMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COMPANION ANIMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CATS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CATS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CATS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CATS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CATS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DOGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DOGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DOGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DOGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DOGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY LIVESTOCK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY LIVESTOCK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CATTLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CATTLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CATTLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CATTLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CATTLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY GOATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY GOATS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY GOATS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY GOATS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY GOATS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY GOATS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SHEEP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SHEEP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SHEEP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SHEEP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SHEEP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SHEEP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SWINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SWINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SWINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SWINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SWINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POULTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POULTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POULTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POULTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POULTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POULTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POULTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CHICKEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CHICKEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CHICKEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CHICKEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CHICKEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CHICKEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TURKEY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TURKEY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TURKEY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TURKEY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TURKEY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TURKEY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)

TABLE